P2X and P2Y receptor antagonists reduce inflammation in ATP-induced microglia

Amer Imraish1, Tuqa Abu-Thiab2, Hana Hammad3

  • 1Department of Biological Sciences, School of Science, The University of Jordan, Amman, Jordan. a.imraish@ju.edu.jo.

Pharmacy Practice
|April 24, 2023
PubMed
Abstract

Insights

Blocking P2X4, P2X7, and P2Y12 receptors in microglia reduces the release of inflammatory cytokines like IL-1β, IL-6, and TNF-α. This finding offers new therapeutic strategies for neuro-inflammation.

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • P2 receptors on microglia are involved in neurotransmitter and pro-inflammatory cytokine release.
  • P2X4, P2X7, and P2Y12 receptors play a role in pain behavior following nerve injury.
  • The impact of blocking these specific P2 receptors on cytokine expression and release in microglia remains unclear.

Purpose of the Study:

  • To investigate the effects of P2X4, P2X7, and P2Y12 antagonists on the expression and release of IL-1β, IL-6, and TNF-α in cultured microglia stimulated with ATP.
  • To determine if specific receptor antagonists can modulate inflammatory responses in microglia.

Main Methods:

  • Utilized real-time fluorescence quantitative PCR to measure mRNA expression of cytokines.
  • Employed enzyme-linked immunosorbent assay (ELISA) to quantify cytokine release.
  • Tested specific antagonists: A-740003 (P2X4), PSB-12062 (P2X7), and MRS 2395 (P2Y12).

Main Results:

  • ATP stimulation increased IL-1β, IL-6, and TNF-α mRNA expression and release.
  • P2X4 and P2X7 antagonists (A-740003 and PSB-12062) significantly inhibited ATP-evoked cytokine mRNA expression and release.
  • The P2Y12 antagonist (MRS 2395) also inhibited ATP-evoked cytokine expression and release, with combined P2X4/P2X7 antagonism showing near-complete blockade.

Conclusions:

  • P2X4, P2X7, and P2Y12 receptors mediate ATP-induced inflammatory cytokine production in microglia.
  • Targeting these P2 receptors presents a potential therapeutic strategy for neuro-inflammatory conditions.
  • Findings provide a basis for developing novel treatments for diseases involving microglial activation and neuro-inflammation.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
572
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
229
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.7K